argenx SE (NASDAQ:ARGX) Q4 2023 Results Conference Call February 29, 2024 8:30 AM ET

Company Participants

Beth DelGiacco - VP and Global Head, Corporate Communications and Investor Relations

Tim Van Hauwermeiren - Chief Executive Officer

Karl Gubitz - Chief Financial Officer

Karen Massey - Chief Operating Officer

Conference Call Participants

Tazeen Ahmad - Bank of America

Derek Archila - Wells Fargo

Rajan Sharma - Goldman Sachs

Yatin Suneja - Guggenheim

Yaron Werber - TD Cowen

Allison Bratzel - Piper Sandler

Vikram Purohit - Morgan Stanley

Joel Beatty - Baird

Simon Baker - Redburn

Suzanne van Voorthuizen - VLK Kempen

Alex Thompson - Stifel

Samantha Semenkow - Citi

Gavin Clark-Gartner - Evercore ISI

Myles Minter - William Blair

Xian Deng - UBS

Douglas Tsao - H.C. Wainwright

Andy Chen - Wolfe Research

Operator

Good morning. My name is Rob, and I will be your conference operator today. I would like to welcome everyone to the call. At this time, all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

I'd like to introduce Beth DelGiacco, Vice President, Global Head of Corporate Communications and Investor Relations. You may now begin your conference.

Beth DelGiacco

Thank you. A press release was issued earlier today with our full year financial results and recent business update. This can be found on our website, along with the presentation for today's webcast.

Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones.

Actual results may differ materially from those indicated by these statements. Argenx is not under any obligation to update statements regarding the future or to conform those statements in relation to actual results unless required by law.

I'm joined on the call today by Tim Van Hauwermeiren, Chief Executive Officer; Karl Gubitz, Chief Financial Officer; and Karen Massey, Chief Operating Officer.

I'll now turn the call to Tim.

Tim Van Hauwermeiren

Thank you, Beth, and welcome everyone. I'll begin on Slide 3. It has been an over year of incredible execution by the argenx team, setting us up to build on this momentum for the year ahead. At the core of everything we do is our mission to transform the lives of patients suffering from autoimmune diseases, and today, we are in a better position than ever to deliver on this mission, reaching more patients globally with our first-in-class innovation and bringing hope to the autoimmune community on what a novel treatment can offer.